Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome
A Delluc, N Limal, X Puéchal, C Francès… - Annals of the …, 2008 - ard.bmj.com
Annals of the rheumatic diseases, 2008•ard.bmj.com
Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome | Annals of the
Rheumatic Diseases Skip to main content Viewing from: Google Indexer BMJ Journals
Subscribe Log In More Log in via Institution Log in via OpenAthens Log in using your
username and password For personal accounts OR managers of institutional accounts
Username * Password * Forgot your log in details?Register a new account? Forgot your user
name or password? Basket Search More Search for this keyword Advanced search Annals of …
Rheumatic Diseases Skip to main content Viewing from: Google Indexer BMJ Journals
Subscribe Log In More Log in via Institution Log in via OpenAthens Log in using your
username and password For personal accounts OR managers of institutional accounts
Username * Password * Forgot your log in details?Register a new account? Forgot your user
name or password? Basket Search More Search for this keyword Advanced search Annals of …
DISCUSSION
The efficacy of IL-1Ra, a specific intervention, is evidence that IL-1 plays a major pathophysiological role in SS, whereas the lack of efficacy of adalimumab refutes the role of tumour necrosis factor (TNF).
ard.bmj.com